Suppr超能文献

相似文献

1
Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan.
J Med Virol. 2021 May;93(5):3211-3218. doi: 10.1002/jmv.26899. Epub 2021 Mar 9.
5
Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
J Med Virol. 2021 May;93(5):2857-2866. doi: 10.1002/jmv.26741. Epub 2021 Mar 1.
6
Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
Virol Sin. 2020 Dec;35(6):744-751. doi: 10.1007/s12250-020-00268-5. Epub 2020 Jul 27.
7
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Front Immunol. 2021 Mar 15;12:614436. doi: 10.3389/fimmu.2021.614436. eCollection 2021.
9
SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity.
Am J Trop Med Hyg. 2021 Jun 17;105(2):395-400. doi: 10.4269/ajtmh.20-1594.
10
Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
J Med Virol. 2021 Feb;93(2):803-811. doi: 10.1002/jmv.26303. Epub 2020 Jul 27.

引用本文的文献

1
National and sub-national sero-epidemiology of immunoglobulin G against SARS-CoV-2 in Iran in 2021.
PLoS One. 2025 Jul 31;20(7):e0313795. doi: 10.1371/journal.pone.0313795. eCollection 2025.
2
Persistence and decay of neutralizing antibody responses elicited by SARS-CoV-2 infection and hybrid immunity in a Canadian cohort.
Microbiol Spectr. 2025 Apr;13(4):e0133324. doi: 10.1128/spectrum.01333-24. Epub 2025 Feb 19.
3
Associations between ethnicity and persistent physical and mental health symptoms experienced as part of ongoing symptomatic COVID-19.
PLoS One. 2024 Oct 31;19(10):e0312719. doi: 10.1371/journal.pone.0312719. eCollection 2024.
4
Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.
EJHaem. 2024 May 29;5(4):661-668. doi: 10.1002/jha2.932. eCollection 2024 Aug.
7
A handheld luminometer with sub-attomole limit of detection for distributed applications in global health.
PLOS Glob Public Health. 2024 Feb 21;4(2):e0002766. doi: 10.1371/journal.pgph.0002766. eCollection 2024.
8
A stronger antibody response in increased disease severity of SARS-CoV-2.
BMC Infect Dis. 2024 Jan 2;24(1):17. doi: 10.1186/s12879-023-08923-4.
10
Non-neutralizing functions in anti-SARS-CoV-2 IgG antibodies.
Biomed J. 2024 Feb;47(1):100666. doi: 10.1016/j.bj.2023.100666. Epub 2023 Sep 29.

本文引用的文献

1
Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals.
Front Microbiol. 2020 Oct 19;11:584251. doi: 10.3389/fmicb.2020.584251. eCollection 2020.
3
Not just antibodies: B cells and T cells mediate immunity to COVID-19.
Nat Rev Immunol. 2020 Oct;20(10):581-582. doi: 10.1038/s41577-020-00436-4.
4
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.
N Engl J Med. 2020 Sep 10;383(11):1085-1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.
5
SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity.
Am J Clin Pathol. 2020 Sep 8;154(4):459-465. doi: 10.1093/ajcp/aqaa123.
6
Kinetics of viral load and antibody response in relation to COVID-19 severity.
J Clin Invest. 2020 Oct 1;130(10):5235-5244. doi: 10.1172/JCI138759.
7
High neutralizing antibody titer in intensive care unit patients with COVID-19.
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.
8
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
10
Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression.
Emerg Microbes Infect. 2020 Dec;9(1):1096-1101. doi: 10.1080/22221751.2020.1766382.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验